Gemzar.com for Patients and Caregivers – Information from Eli Lilly & Company About Treatment with GEMZAR for Non-Small Cell Lung Cancer

GEMZAR (gemcitabine HCl for injection) for Lung, Pancreatic, and Breast Cancer Home

GEMZAR (gemcitabine HCl for injection): Understanding Cancer

GEMZAR (gemcitabine HCI for injection): Beginning Therapy

GEMZAR (gemcitabine HCl for injection): Treatment with GEMZAR

GEMZAR (gemcitabine HCl for injection): Life Stories

GEMZAR (gemcitabine HCl for injection): For Caregivers

Understanding Non-Small Cell Lung Cancer and Treatment

GEMZAR (gemcitabine HCl for injection): Lung Cancer Resources

Non-small cell lung cancer (NSCLC) is one of the two main types of lung cancer. About 75-80% of all people diagnosed with lung cancer have NSCLC, which is less aggressive than small cell lung cancer (SCLC). If you or a loved one is affected by NSCLC, these resources can help you to understand more about lung cancer and your treatment options.

Information About Non-Small Cell Lung Cancer

There are three major subtypes of non-small cell lung cancer (NSCLC). Use the links below to get a better understanding of how these subtypes are diagnosed.

Learn About Treatment Options
These worksheets and guides can be helpful when considering your treatment options and making important decisions about your non-small cell lung cancer therapy.

Treatment Options Worksheet
Questions to consider about your treatment.

Making Therapy Decisions
Choosing your healthcare team and therapies.

Starting Chemotherapy
Understanding side effects and choices involved.

GEMZAR for Non-Small Cell Lung Cancer

GEMZAR is indicated in combination with cisplatin (another type of chemotherapy) for the first-line treatment or patients with locally advanced (stage IIIA or stage IIIb) or metastatic (stage IV or cancer that has spread) non-small cell lung cancer for whom surgery is not possible.
Find out more about GEMZAR and NSCLC.

Click the icon above to download a FREE copy of the Adobe Reader

Privacy Statement | Prescribing Information | Safety Information | Terms of Use
Copyright © 2008 Eli Lilly and Company. All rights reserved. This site is intended for U.S. residents age 18 and over. For more information about cancer, contact your doctor or other healthcare professional. GEMZAR® is a registered trademark of Eli Lilly and Company. GC 28281

About GEMZAR

GEMZAR in combination with paclitaxel is approved by the FDA for the first-line treatment of patients with metastatic breast cancer after they have received another type of chemotherapy called an anthracycline, unless their medical condition did not allow them to receive an anthracycline.

GEMZAR is indicated in combination with cisplatin (another type of chemotherapy) for the first-line treatment of patients with locally advanced (stage IIIA or stage IIIB) or metastatic (stage IV or cancer that has spread) non-small cell lung cancer for whom surgery is not possible.

GEMZAR is indicated as a single agent (given alone) as the first-line treatment for patients with locally advanced (stage II or stage III when surgery is not an option) or metastatic (stage IV) adenocarcinoma of the pancreas. GEMZAR is also indicated for patients previously treated with 5-FU (another type of chemotherapy).

GEMZAR is indicated in combination with carboplatin (another type of chemotherapy) for the woman with ovarian cancer that has returned at least 6 months after the patient had finished platinum-based therapy.

Important Safety Information

GEMZAR may not be appropriate for some patients.

If you are allergic to GEMZAR, tell your doctor you should not receive it. GEMZAR can suppress bone marrow function. There have been rare reports of serious kidney or liver toxicity with GEMZAR treatment, sometimes fatal. Serious lung toxicity has also been reported, sometimes fatal. If you think you are pregnant, are planning to be pregnant, or are nursing, please tell your healthcare team. GEMZAR may harm your unborn or nursing baby.

If you have had prior kidney or liver problems or impairment, please tell your healthcare professional. GEMZAR may not be right for you. GEMZAR has not been shown to work in children. Tell your doctor if you are taking other medicines, including prescription and non-prescription medicines, vitamins, or herbal supplements.

There is a risk of side effects associated with GEMZAR therapy. The most common side effects are low blood cell counts (red blood cells, white blood cells, and platelets); fever; infection; hair loss; tiredness; nausea, vomiting, constipation, and diarrhea; rash; shortness of breath; muscle aches; and numbness or tingling in your toes or fingers. These are not all of the side effects of GEMZAR. If you have any side effect that bothers you or that doesn't go away, be sure to talk with your healthcare professional. Call your healthcare professional right away if you have fever or chills. These symptoms could mean you have an infection.

You will have regular blood tests before and during your treatment with GEMZAR. Your doctor may adjust your dose of GEMZAR or delay your treatment based on the results of your blood test and on your general condition.

For more information about all of the side effects of GEMZAR, please talk with your healthcare team, see the complete Prescribing Information, or call 1-800-545-5979.

SG-22